Your browser doesn't support javascript.
loading
Cancer Alters the Metabolic Fingerprint of Extracellular Vesicles.
Palviainen, Mari; Laukkanen, Kirsi; Tavukcuoglu, Zeynep; Velagapudi, Vidya; Kärkkäinen, Olli; Hanhineva, Kati; Auriola, Seppo; Ranki, Annamari; Siljander, Pia.
Afiliação
  • Palviainen M; EV group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, 00790 Helsinki, Finland.
  • Laukkanen K; CURED, Drug Research Program, Faculty of Pharmacy, Division of Pharmaceutical Biosciences, University of Helsinki, 00790 Helsinki, Finland.
  • Tavukcuoglu Z; EV-core, Faculty of Biological and Environmental Sciences, University of Helsinki, 00790 Helsinki, Finland.
  • Velagapudi V; Department of Dermatology and Allergology, Clinicum, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.
  • Kärkkäinen O; EV group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, 00790 Helsinki, Finland.
  • Hanhineva K; CURED, Drug Research Program, Faculty of Pharmacy, Division of Pharmaceutical Biosciences, University of Helsinki, 00790 Helsinki, Finland.
  • Auriola S; Metabolomics Unit, Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00290 Helsinki, Finland.
  • Ranki A; LC-MS Metabolomics Center, School of Pharmacy, University of Eastern Finland, 70211 Kuopio, Finland.
  • Siljander P; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, 70211 Kuopio, Finland.
Cancers (Basel) ; 12(11)2020 Nov 06.
Article em En | MEDLINE | ID: mdl-33172086
ABSTRACT
Cancer alters cell metabolism. How these changes are manifested in the metabolite cargo of cancer-derived extracellular vesicles (EVs) remains poorly understood. To explore these changes, EVs from prostate, cutaneous T-cell lymphoma (CTCL), colon cancer cell lines, and control EVs from their noncancerous counterparts were isolated by differential ultracentrifugation and analyzed by nanoparticle tracking analysis (NTA), electron microscopy (EM), Western blotting, and liquid chromatography-mass spectrometry (LC-MS). Although minor differences between the cancerous and non-cancerous cell-derived EVs were observed by NTA and Western blotting, the largest differences were detected in their metabolite cargo. Compared to EVs from noncancerous cells, cancer EVs contained elevated levels of soluble metabolites, e.g., amino acids and B vitamins. Two metabolites, proline and succinate, were elevated in the EV samples of all three cancer types. In addition, folate and creatinine were elevated in the EVs from prostate and CTCL cancer cell lines. In conclusion, we present the first evidence in vitro that the altered metabolism of different cancer cells is reflected in common metabolite changes in their EVs. These results warrant further studies on the significance and usability of this metabolic fingerprint in cancer.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article